EAST BRUNSWICK, N.J., Oct. 1, 2009 (GLOBE NEWSWIRE) -- Savient Pharmaceuticals, Inc. (Nasdaq:SVNT) today announced that Paul Hamelin, President of Savient Pharmaceuticals, will be presenting at the upcoming JMP Securities 4th Annual Healthcare Focus Conference on October 6, 2009.
The presentation is scheduled to begin on Tuesday, October 6, 2009 at 2:30 p.m. Eastern Time. The conference will be held at The New York Palace Hotel in New York, NY, October 5-6, 2009.
Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' Web site, http://www.savient.com. A replay of the webcast will be available on the Company's Web site for 30 days.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and marketing pharmaceutical products that target unmet medical needs in both niche and broader specialty markets. Savient has developed one product: KRYSTEXXA(TM) (pegloticase) which is a PEGylated uricase enzyme intended for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Further information on Savient can be accessed by visiting: http://www.savient.com. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
SVNT - G